- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Pacira Pharmaceuticals Inc (PCRX)
Pacira Pharmaceuticals Inc stock price live, this page displays NASDAQ PCRX stock exchange data. View the PCRX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Pacira Pharmaceuticals Inc real time stock price chart below.
What Is the Pacira Pharmaceuticals Inc Stock Price Today?
The Pacira Pharmaceuticals Inc stock price today is 24.43.
What Is the Stock Symbol for Pacira Pharmaceuticals Inc?
The stock symbol for Pacira Pharmaceuticals Inc is "PCRX."
What Stock Exchange Does Pacira Pharmaceuticals Inc Trade On?
Pacira Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Pacira Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Pacira Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PCRX quote. (ISIN: US6951271005)
What Is the Pacira Pharmaceuticals Inc Stock Price Today?
The Pacira Pharmaceuticals Inc stock price today is 24.43.
What Is the Stock Symbol for Pacira Pharmaceuticals Inc?
The stock symbol for Pacira Pharmaceuticals Inc is "PCRX."
What Stock Exchange Does Pacira Pharmaceuticals Inc Trade On?
Pacira Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Pacira Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Pacira Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PCRX quote. (ISIN: US6951271005)
24.48
-0.88(-3.47%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
24.31
25.43
52 wk Range
18.80
27.64
Earnings results expected in 6 days
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
24.3125.43
52 wk Range
18.8027.64
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
PCRX Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
28.71
Upside
+17.30%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Net income is expected to grow this year
- Form 144 Pacira BioSciences For: 22 April
- Investing.com
- Form 144 Pacira BioSciences For: 21 April
- Investing.com
- Form 144 Pacira BioSciences For: 22 April
- Investing.com
- Form 144 Pacira BioSciences For: 21 April
- Investing.com
- Form 144 Pacira BioSciences For: 20 April
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product for use in animals. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Brisbane, California.
Pacira Pharmaceuticals Inc SWOT Analysis
Patent Peril | Explore Pacira's battle against generic competition as legal challenges threaten its flagship product Exparel, potentially eroding market share and revenues |
NOPAIN, Big Gain? | Delve into Pacira's NOPAIN initiative and new partnerships, offering hope for growth amid challenges in the non-opioid pain management market |
Outpatient Opportunity | Learn how recent CMS rule changes could boost Pacira's Exparel and iovera adoption in outpatient settings, expanding market reach |
Financial Fortitude | Analysts set price targets ranging from $14 to $37, with Pacira's strong margins and cash flow suggesting resilience despite market headwinds |
Pacira Pharmaceuticals Inc Earnings Call Summary for Q4/2025
- Pacira missed Q4 2025 forecasts with EPS of $0.57 vs. $0.90 expected and revenue of $196.9M vs. $200.54M, stock fell 3.71% to $23.46.
- EXPAREL sales increased 5.5% year-over-year with 7% volume growth; company achieved record 80% non-GAAP gross margin in Q4.
- Operating expenses surged significantly: non-GAAP R&D up 56.4% to $34.4M and SG&A up 30.2% to $91.9M year-over-year.
- FY2026 guidance projects EPS between $0.77-$1.02 and quarterly revenue of $187.9M-$207.14M, focusing on EXPAREL expansion and partnerships.
- CEO Stack emphasized operational efficiency and innovation despite challenges; stock down 12.71% YTD, trading near 52-week low of $18.80.
Last Updated: 2026-02-26, 05:34 p/m
Read Full TranscriptCompare PCRX to Peers and Sector
Metrics to compare | PCRX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPCRXPeersSector | |
|---|---|---|---|---|
P/E Ratio | 140.9x | 20.2x | −0.4x | |
PEG Ratio | 1.33 | 0.33 | 0.00 | |
Price/Book | 1.4x | 2.5x | 2.6x | |
Price / LTM Sales | 1.4x | 2.5x | 3.2x | |
Upside (Analyst Target) | 8.6% | 51.5% | 46.7% | |
Fair Value Upside | Unlock | 40.9% | 7.6% | Unlock |
Analyst Ratings
4 Buy
2 Hold
1 Sell
Ratings:
7 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 28.71
(+17.30% Upside)
Earnings
Latest Release
Feb 26, 2026
EPS / Forecast
0.57 / 0.90
Revenue / Forecast
196.9M / 200.54M
People Also Watch
FAQ
What Is the Pacira (PCRX) Stock Price Today?
The Pacira stock price today is 24.48 USD.
What Stock Exchange Does Pacira Trade On?
Pacira is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Pacira?
The stock symbol for Pacira is "PCRX."
What Is the Pacira Market Cap?
As of today, Pacira market cap is 987.14M USD.
What Is Pacira's Earnings Per Share (TTM)?
The Pacira EPS (TTM) is 0.16.
When Is the Next Pacira Earnings Date?
Pacira will release its next earnings report on Apr 30, 2026.
From a Technical Analysis Perspective, Is PCRX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Pacira Stock Split?
Pacira has split 0 times.
How Many Employees Does Pacira Have?
Pacira has 827 employees.
What is the current trading status of Pacira (PCRX)?
As of Apr 24, 2026, Pacira (PCRX) is trading at a price of 24.48 USD, with a previous close of 25.36 USD. The stock has fluctuated within a day range of 24.31 USD to 25.43 USD, while its 52-week range spans from 18.80 USD to 27.64 USD.
What Is Pacira (PCRX) Price Target According to Analysts?
The average 12-month price target for Pacira is 28.71 USD, with a high estimate of 38 USD and a low estimate of 22 USD. 4 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +17.30% Upside potential.
What Is the PCRX Premarket Price?
PCRX's last pre-market stock price is 25.15 USD. The pre-market share volume is 1,610.00, and the stock has decreased by -0.21, or -0.83%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.